Does Tirzepatide Cause Hair Loss? What Trials and FDA Reports Show on Tirzepatide Hair Loss

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

Tirzepatide hair loss is real, though most trial participants don't get it. In the trials behind Zepbound's label, 4–5% of participants on tirzepatide reported hair loss vs 1% on placebo, and the label ties it to weight reduction. Experts suspect temporary shedding from fast weight loss, but no tirzepatide study has tracked regrowth. Evidence: Well-established (more common than placebo); Limited (cause, timing and recovery).

Key takeaways

• Zepbound's label reports hair loss in 5%, 4% and 5% of trial participants on 5, 10 and 15 mg vs 1% on placebo, and links it to weight reduction (Zepbound label).
• Mounjaro, the same drug sold for type 2 diabetes, lists alopecia only under postmarketing experience (Mounjaro label).
• A 2026 meta-analysis of 9 interventional studies (4,114 GLP-1 users) found hair loss 3.25 times as likely as on placebo (Cheng et al., 2026).
• In our analysis of FDA adverse-event reports, the share of tirzepatide reports listing hair loss rose from 0.97% in late 2024 to 2.63% in mid-2026 (our FAERS study). That is a reporting signal, not your personal odds.
• A 2026 expert commentary states that no prospective, controlled study has examined GLP-1 hair loss and that causality has not been established (Piraccini et al., 2026).

This page covers hair within our guide to GLP-1 skin changes. For tirzepatide's other skin reactions, see Zepbound skin side effects and Mounjaro skin sensitivity.

Does tirzepatide cause hair loss?

Hair loss is more common on tirzepatide than on placebo in trials, but nobody has proven the drug itself is the cause rather than the weight loss it produces. The Zepbound label says hair loss in treated patients was "associated with weight reduction" (Zepbound label).

Three kinds of evidence exist, and they answer different questions. Trials tell you how often participants reported hair loss compared with placebo. FDA reports show what people report in the real world. Reviews offer expert interpretation.

Our own data add one new finding: Hair loss reports for Mounjaro/Zepbound nearly tripled as a share of FDA reports in 18 months. The full methods are in our FDA data study on GLP-1 skin and hair reports. A 2025 scoping review counted more than 1,000 FAERS hair-loss cases across GLP-1 drugs but concluded that "a causal relationship cannot be confirmed" (Rojas Lopez et al., 2025).

If you're shedding, talk to your prescriber or a dermatologist. Don't stop or change your dose on your own.

Evidence: Well-established (more common than placebo); Limited (causation).

How common is tirzepatide hair loss on Zepbound and Mounjaro?

In the pooled Zepbound trials (Study 1 and 2), 4–5% of participants on tirzepatide reported hair loss vs 1% on placebo. Mounjaro's label gives no trial rate because hair loss appears only in its postmarketing section.

Sources: Zepbound label, effective Aug 28, 2026; Mounjaro label, effective Jul 29, 2026. The two products have different labels and trial programs.

Zepbound's label lists hair loss among its most common adverse reactions (5% or more). No Zepbound-treated participants stopped treatment because of hair loss; one placebo participant did.

Across the GLP-1 class, a 2026 systematic review and meta-analysis pooled 9 interventional studies (7 RCTs, 2 non-randomized) with 4,114 GLP-1 users. The risk ratio vs placebo was 3.252 (95% CI 1.437–7.358), rising to 3.587 in obesity RCTs, and 3.9% of participants reported hair loss in a single-arm analysis. The authors declared no competing interests (Cheng et al., 2026).

Reviews land in the same range. A 2026 review chapter puts trial rates at about 3%–5%, with a risk ratio of about 3.3 (Bridges & Jackson, 2026). That figure likely restates the Cheng meta-analysis, so treat it as a summary rather than separate confirmation. A narrative review cites 3–7% in controlled trials (Leite Júnior & Ribeiro Junior, 2026), and a JAAD CME review lists alopecia among GLP-1 dermatologic reactions (Narla & Narla, 2026).

Evidence: Well-established (more common than placebo in trials).

What do FDA reports show about tirzepatide hair loss?

FDA reports show a rising share of tirzepatide reports that list hair loss, and a reporting odds ratio whose confidence interval sits above 1. They can't show how often hair loss happens or whether tirzepatide caused it.

We pulled FAERS data through openFDA on Oct 10, 2026 (data through July 30, 2026), searching the generic names tirzepatide and semaglutide. Of 160,782 tirzepatide reports (2022Q3–2026Q2), 2,635 listed alopecia (1.64%). Of 100,857 semaglutide reports (2018Q1–2026Q2), 1,085 did (1.08%). Methods and full tables are in our FDA adverse-event study.

The tirzepatide share went from 0.97% (92 reports) in 2024Q4 to 2.72% (531) in 2026Q1 and 2.63% (524) in 2026Q2. For comparison, 0.84% of semaglutide reports listed hair loss in 2026Q2.

Compared with all other drugs in FAERS, the reporting odds ratio (ROR, how much more often an event is reported with one drug than with others) was 1.77 (95% CI 1.70–1.84) for tirzepatide and 1.15 (1.08–1.22) for semaglutide. Both intervals sit above 1. Note: the ROR was computed on our CSV contingency table, whose alopecia counts (2,639 tirzepatide, 1,086 semaglutide) differ slightly from the counts above.

FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens. Reports are voluntary and include duplicates. The share can rise with publicity and with prescribing, and there is no denominator of people taking the drug.

Published FAERS studies disagree. An analysis of six GLP-1 drugs from Q2 2022 to Q2 2025 found an adjusted signal for semaglutide (aROR 1.23, 1.11–1.35) but "lower or non-significant" signals for tirzepatide (Lee & Kim, 2026). The difference from our result likely reflects different methods and time windows.

A study of four pharmacovigilance databases (FAERS data Q4/2003 to Q3/2023) found no positive hair-loss signal for GLP-1 drugs by its criteria (PRR above 2 and χ² above 4), although GLP-1 drugs were the most-reported class for hair loss. Semaglutide, liraglutide and dulaglutide led; the authors declared no competing interests (Nakhla et al., 2025). Our ROR shouldn't be read as meeting that study's threshold.

Evidence: Mixed / contested (reporting signals disagree across analyses).

Is hair loss more common on tirzepatide than on Ozempic?

Probably, but it isn't settled. No head-to-head trial has compared hair loss on tirzepatide and semaglutide. The largest real-world comparison, a preprint that hasn't been peer-reviewed, points to tirzepatide, while one FDA-report analysis points the other way.

• Head-to-head records (preprint, not peer-reviewed). In US health records, 12,863 tirzepatide users were matched to 12,863 semaglutide users. New hair loss within 12 months was recorded in 4.20% vs 2.88% (risk ratio 1.46); the gap was 1.55% vs 1.24% at 6 months. After also matching on weight lost (11,046 per group), it was 4.24% vs 3.33% (risk ratio 1.27), so weight loss explained part of the gap, not all of it (Marwaha et al., 2026 preprint). It is observational and authored by nference, the data company that ran it.
• Tirzepatide vs other options. A TriNetX study of 218,147 GLP-1 users found tirzepatide carried a higher risk of telogen effluvium than other weight-loss medicines (hazard ratio 2.65), but no higher risk than bariatric surgery (hazard ratio 1.61). It found no increased risk for semaglutide or liraglutide (Neubauer et al., 2025; figures from the table in Gupta et al., 2026). The authors suggest tirzepatide's larger weight loss may explain this.

• Trial data. In SURMOUNT-3, 7% of tirzepatide users (20/287) reported alopecia vs 1.4% (4/292) on placebo, as tabulated in the Gupta review.

• A 2026 systematic review of 24 studies found semaglutide and tirzepatide had the highest incidence rates of hair loss among GLP-1 drugs (Gupta et al., 2026).

• A 2026 narrative review says tirzepatide shows "stronger associations" with shedding than older GLP-1 drugs (Leite Júnior & Ribeiro Junior, 2026).
• The Lee FAERS study found the reverse: a signal for semaglutide, not tirzepatide (Lee & Kim, 2026).
• Our ROR is higher for tirzepatide (1.77 vs 1.15), but that compares reporting patterns, not how many people lose hair.

For semaglutide trial rates and dose findings, see our Ozempic hair loss guide.

Evidence: Mixed / contested.

Why does tirzepatide hair loss happen?

The leading explanation is telogen effluvium, a temporary, diffuse shed that happens when a stressor pushes many growing hairs into their resting phase at once. Rapid weight loss is the suspected trigger, but a direct drug effect hasn't been ruled out.

A 2025 review of GLP-1 skin effects describes hair loss "particularly in the form of telogen effluvium," potentially linked to rapid weight loss. One author consults for Eli Lilly and other drug makers (Burke et al., 2025). The Gupta review found tirzepatide, which produces the greatest weight loss of the drugs reviewed, was most often linked to telogen effluvium (Gupta et al., 2026).

The 2026 review chapter adds caloric restriction, hormonal shifts and nutritional shortfalls. It also proposes a direct effect on follicles through GLP-1 receptors in dermal white adipose tissue, the fat layer around hair roots. That last idea is a hypothesis (Bridges & Jackson, 2026).

Bariatric surgery offers a comparison. In a 2-year prospective study of 31 surgical patients, 17 (54.84%) developed acute telogen effluvium (Triwatcharikorn et al., 2023). The Bridges chapter cites pooled bariatric incidence of 47%–57%. A narrative review links post-surgical shedding to weight loss, low calorie and protein intake, micronutrient deficiency and anesthesia; its authors declared no conflicts (Smolarczyk et al., 2024).

A drug effect beyond weight loss is now plausible. In a Penn Medicine target-trial emulation of adults with type 2 diabetes, GLP-1 drugs as a class were linked to more hair loss than SGLT-2 inhibitors (hazard ratio 1.37, 95% CI 1.08–1.73) and DPP-4 inhibitors (1.68, 1.28–2.20). The link was specific to non-scarring hair loss, the authors note the absolute risk is low, and the study grouped GLP-1 drugs rather than isolating tirzepatide (Tang et al., 2026).

Pattern hair loss is a separate issue. Not all shedding on these drugs is temporary telogen effluvium. A 2026 genetic (Mendelian randomization) study in men suggests that higher GLP-1 receptor expression may raise the risk of male-pattern hair loss (Ramessur et al., 2026). It used lifelong genetic differences, not people taking the drugs, so it's a hypothesis-generating signal. Pattern hair loss doesn't resolve on its own, which is another reason to get a dermatologist's diagnosis.

One finding complicates the weight-loss story. A FAERS review of six GLP-1 drugs found significantly more alopecia reports when the drugs were used for type 2 diabetes than for weight management (P=0.000) (Daniel et al., 2025). Funding isn't reported in the abstract.

Evidence: Limited (mechanism is expert opinion).

When does hair loss on tirzepatide start, and does it grow back?

No tirzepatide study reports when shedding starts or how long recovery takes. The only timing data come from bariatric surgery, which is an analogy, not tirzepatide evidence.

In one case report, a 24-year-old woman developed diffuse shedding within 7 weeks of bariatric surgery. The authors' review describes acute shedding within the first 3 months, often telogen effluvium, and nutrition-related loss starting around 6 months after surgery. The authors declared financial relationships not detailed in the abstract (Cohen-Kurzrock & Cohen, 2021).

The Leite Júnior review calls GLP-1-related hair loss "predominantly transient and reversible" (Leite Júnior & Ribeiro Junior, 2026). That is expert opinion; no study in our pack followed tirzepatide users until regrowth.

You'll often see "starts at 2–4 months, recovers over 6–12 months." That timeline is clinic convention, not tirzepatide data. A recurring question in GLP-1 communities is whether shedding ends once weight stabilizes; the honest answer is that no tirzepatide study has measured it.

Evidence: Early / preliminary (bariatric data only).

Who is more likely to lose hair on tirzepatide?

Women, based on both the Zepbound trials and reviews. Reviews also flag people who lose more than 10% of their body weight.

In the pooled Zepbound trials, 7.1% of female participants on tirzepatide reported hair loss vs 0.5% of males; on placebo the figures were 1.3% and 0% (Zepbound label). The Gupta review also found females disproportionately affected (Gupta et al., 2026). The Leite Júnior review names female sex and weight reduction above 10% as the most robust predictors (Leite Júnior & Ribeiro Junior, 2026).

A matched records study, posted as a preprint and not yet peer-reviewed, points the same way: 5.44% of women on tirzepatide vs 3.63% on semaglutide had new hair loss within 12 months (8,985 per group; risk ratio 1.50). About 9 in 10 tirzepatide users who developed hair loss were women (Marwaha et al., 2026 preprint).

Dose is less clear. Gupta found a dose effect for semaglutide, but the Zepbound label shows no clear trend: 5% at 5 mg, 4% at 10 mg and 5% at 15 mg.

Evidence: Moderate (female sex); Limited (weight-loss threshold).

How can you reduce hair loss on tirzepatide?

Nothing is proven, because no treatment has been tested for GLP-1-related hair loss. The first step is to tell your prescriber and ask whether a dermatologist should confirm the type of hair loss, since most published studies lacked that confirmation (Rojas Lopez et al., 2025).

The 2026 review chapter suggests these approaches. Treat them as expert opinion, not trial results (Bridges & Jackson, 2026):

• Protein: a target of 1.2–2.0 g/kg/day based on adjusted body weight. Your prescriber or a dietitian can work out what applies to you.
• Counseling: knowing the expected time course of shedding.
• Medicine options: low-dose oral minoxidil, a decision for a dermatologist.

Checking iron, thyroid and other blood levels is common clinic convention; no tirzepatide study in our pack tests it. In the nference preprint, repeated ferritin, iron, B12, folate, vitamin D and zinc tests showed no decline in people who developed hair loss, though few had paired results (Marwaha et al., 2026 preprint).

Do biotin or Nutrafol help? Neither has been tested in GLP-1 users. - Biotin: a 2024 review found the only double-blind, placebo-controlled study showed no difference from placebo (Yelich et al., 2024), and an earlier review found that everyone who improved in 18 case reports had an underlying deficiency or condition (Patel et al., 2017). - Nutrafol: its first placebo-controlled trial was small (26 women on Nutrafol vs 14 on placebo, 6 months) and reported more terminal and vellus hairs (Ablon & Kogan, 2018). A 2026 meta-analysis of 14 supplement studies (967 participants, including Nutrafol) called the results "promising preliminary" and said more independent research is needed (Alanazi et al., 2026).

Don't self-inject GHK-Cu. Some GLP-1 users report injecting copper peptide (GHK-Cu) bought online. We found no human trial of injected GHK-Cu for hair loss, and injecting an unregulated product carries infection and contamination risks. See copper peptides for hair for what the topical evidence shows. Cosmetic scalp serums, including copper peptides for hair and The Ordinary's hair density serum, have no evidence in GLP-1 shedding.

Before your appointment, clinicians often find it helpful if you note the following (clinic convention):

• When the shedding started
• Any recent dose changes
• How much weight you've lost, and how fast
• Your usual diet and protein intake
• Dated photos of your part line

Evidence: Limited (expert opinion only).

Can tirzepatide ever improve hair?

A few reports describe improvement, but there is no controlled evidence. Don't expect regrowth from tirzepatide.

In a 2024 case report, a 57-year-old man with androgenetic alopecia (pattern hair loss) and insulin resistance took tirzepatide alone, 2.5 mg weekly for 3 months and then 5 mg. His hair density improved significantly within 6 months, alongside a 20 lb weight loss. It was a single case with no control; no conflicts were disclosed (Gordon et al., 2024).

A systematic review of 5 studies (2,905 adults) found conflicting results: some showed improvement or regrowth, others hair loss (Alsuwailem et al., 2025). Two 2026 reviews mention "paradoxical improvements" in pattern hair loss and some scarring alopecias (Leite Júnior & Ribeiro Junior, 2026; Bridges & Jackson, 2026).

Evidence: Early / preliminary.

When should you see a doctor about hair loss on Mounjaro or Zepbound?

Tell your prescriber about any shedding, and see a dermatologist to confirm what kind it is. Patchy loss, scalp pain, redness or scaling, or shedding that doesn't settle deserve a closer look; this is clinic convention, not tested guidance.

Pattern hair loss and telogen effluvium were the most frequent subtypes in the one GLP-1 study that described hair-loss patterns (Rojas Lopez et al., 2025). They need different management, which is why a diagnosis matters. If your face is also changing, see Mounjaro face and loose skin after weight loss.

Where the evidence stops

• No prospective controlled studies have specifically evaluated GLP-1 hair loss (Piraccini et al., 2026). Several commentary authors consult for Eli Lilly and other companies.
• Drug vs weight loss is unresolved. The Zepbound label links hair loss to weight reduction, but FAERS data show more reports with diabetes use (Daniel et al., 2025).
• FAERS analyses conflict on whether tirzepatide shows a signal.
• The head-to-head data are a preprint. The tirzepatide-vs-semaglutide comparison hasn't been peer-reviewed, and the genetic pattern-hair-loss study didn't study drug users.
• No tirzepatide timing data. Onset and recovery estimates come from bariatric surgery or clinic convention.
• No tested treatments. Protein targets and minoxidil come from expert review, not trials in GLP-1 users.

FAQ

References

1. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, effective Aug 28, 2026. DailyMed. 2026. Label; pooled Study 1 and 2 adverse-reaction data. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
2. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, effective Jul 29, 2026. DailyMed. 2026. Label; alopecia under postmarketing experience. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0818426a-53eb-4db7-9609-bbae1e7a3964
3. Peptide Skincare Editorial Team. Ozempic Skin Side Effects in FDA Data: Hair Loss, Rash and Itch Reports for Semaglutide and Tirzepatide. Peptide Skincare. 2026. FAERS analysis via openFDA, accessed 2026-10-10. /blog/glp1-skin-hair-side-effects-fda-data/
4. Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2026. 9 studies (7 RCTs), n=4,114; no competing interests. https://pubmed.ncbi.nlm.nih.gov/42155605/
5. Gupta AK, et al. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026. Systematic review, 24 studies; one author has industry trial grants. https://pubmed.ncbi.nlm.nih.gov/41998799/
6. Piraccini BM, et al. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Dermatol Ther (Heidelb). 2026. Commentary; authors report industry ties, including employees of Pierre Fabre. https://pubmed.ncbi.nlm.nih.gov/42249225/
7. Leite Júnior AC, Ribeiro Junior HL. GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?. Acta Diabetol. 2026. Narrative review; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/42873315/
8. Bridges AG, Jackson T. Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice. Clin Dermatol. 2026. Review chapter; no relevant conflicts declared. https://pubmed.ncbi.nlm.nih.gov/42767469/
9. Burke OM, et al. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disord. 2025. Review; one author consults for Eli Lilly and others. https://pubmed.ncbi.nlm.nih.gov/41058954/
10. Rojas Lopez RF, et al. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025. Scoping review, 9 studies; no funding. https://pubmed.ncbi.nlm.nih.gov/40951222/
11. Alsuwailem OA, et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025. Systematic review, 5 studies, n=2,905; no funding. https://pubmed.ncbi.nlm.nih.gov/41111833/
12. Lee N, Kim Y. Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes Metab Res Rev. 2026. FAERS disproportionality, Q2 2022–Q2 2025, 6 drugs; no conflicts. https://pubmed.ncbi.nlm.nih.gov/41886296/
13. Nakhla M, et al. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. Cardiovasc Drugs Ther. 2025. 4 pharmacovigilance databases; no competing interests. https://pubmed.ncbi.nlm.nih.gov/39264502/
14. Daniel S, et al. A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J Drugs Dermatol. 2025. Retrospective FAERS review, 6 drugs; funding not reported. https://pubmed.ncbi.nlm.nih.gov/40196945/
15. Narla S, Narla RR. JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology. J Am Acad Dermatol. 2026. CME review. https://pubmed.ncbi.nlm.nih.gov/41698604/
16. Triwatcharikorn J, et al. Skin manifestations and biophysical changes following weight reduction induced by bariatric surgery: A 2-year prospective study. J Dermatol. 2023. Prospective, n=31, 2 years. https://pubmed.ncbi.nlm.nih.gov/37665164/
17. Cohen-Kurzrock RA, Cohen PR. Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report and a Review of Hair Loss Following Weight Loss Surgery. Cureus. 2021. Case report (n=1) and review; authors declared financial relationships. https://pubmed.ncbi.nlm.nih.gov/34055500/
18. Smolarczyk K, et al. Association of Obesity and Bariatric Surgery on Hair Health. Medicina (Kaunas). 2024. Narrative review; no conflicts. https://pubmed.ncbi.nlm.nih.gov/38399612/
19. Gordon ER, et al. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep. 2024. Case report, n=1, 6 months; none disclosed. https://pubmed.ncbi.nlm.nih.gov/39135763/
20. Neubauer Z, Ong MM, Singal A, Lipner SR. Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: A retrospective cohort TriNetX database study. J Am Acad Dermatol. 2025. Retrospective cohort, n=218,147 GLP-1 users; no funding. Figures as tabulated in Gupta 2026 (no PubMed abstract). https://pubmed.ncbi.nlm.nih.gov/40848975/
21. Tang H, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026. Target trial emulation, ~12,000 GLP-1 initiators per comparison. https://pubmed.ncbi.nlm.nih.gov/42486607/
22. Ramessur R, et al. A causal effect of increased GLP1R expression on male-pattern hair loss is suggested by 2-sample Mendelian randomization. J Invest Dermatol. 2026. Research letter, Mendelian randomization; no PubMed abstract. https://pubmed.ncbi.nlm.nih.gov/42692190/
23. Marwaha A, et al. New-onset alopecia is significantly higher with tirzepatide than with semaglutide, even after weight-loss matching. Preprints.org. 2026. Preprint, NOT peer-reviewed; matched EHR cohort, n=12,863 per arm, 12 months; nference authors. https://doi.org/10.20944/preprints202607.1370.v1
24. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018. RCT, n=40 (26 vs 14), 6 months; Nutrafol Women's; funding not stated in abstract. https://pubmed.ncbi.nlm.nih.gov/29742189/
25. Alanazi R, et al. Evaluating the effectiveness of commercial oral supplements for hair growth: a systematic review and meta-analysis. J Cosmet Dermatol. 2026. 14 studies, n=967. https://pubmed.ncbi.nlm.nih.gov/41954038/
26. Yelich A, et al. Biotin for hair loss: teasing out the evidence. J Clin Aesthet Dermatol. 2024. Review, 3 qualifying studies. https://pubmed.ncbi.nlm.nih.gov/39148962/
27. Patel DP, et al. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017. Review, 18 cases. https://pubmed.ncbi.nlm.nih.gov/28879195/

Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Never stop or change a prescribed medication on your own; talk to your prescriber, and see a dermatologist to confirm the type of hair loss.

For educational purposes only; not medical advice. See our disclaimer and research method.